inclusion criteria: subject inclusion criteria 1. patient or legally authorized representative (lar) willing and able to provide written or electronic or otherwise fda-acceptable informed consent based on current fda regulations. 2. hospitalized male or non-pregnant female 3. rt-pcr confirmed sars-cov-2 using who consensus or validated primers 4. meet the following criteria: 1. deficiency in oxygenation as defined by the berlin ards criteria (27): timing: within 1 week of onset of symptoms imaging: bilateral pulmonary infiltrates oxygenation (any): mild: 200 mmhg \< pao2/fio2 ≤ 300 mmhg moderate: 100 mmhg \< pao2/fio2 ≤ 200 mmhg severe: pao2/fio2 ≤ 100 mmhg and 2. requiring oxygen support in the form of high flow nasal cannula (hfnc), non-invasive positive pressure ventilation, intubation and mechanical ventilation, or initiation of ecmo and 3. any one or more of the following: 1. elevated crp (\>10 gm/dl) 2. elevated ferritin (\>1000) 3. neutrophil/lymphocyte ratio \>3.3 5. patient will receive current clinical standard of care. this includes inpatient use of remdesivir, dexamethasone, convalescent plasma, or pre-hospitalization outpatient treatment with casirivimab and imdevima 6. age ≥ 18 years

inclusion criteria: subject inclusion criteria 1. patient or legally authorized representative (lar) willing and able to provide written or electronic or otherwise fda-acceptable informed consent based on current fda regulations. 2. hospitalized male or non-pregnant female 3. rt-pcr confirmed sars-cov-2 using who consensus or validated primers 4. meet the following criteria: 1. deficiency in oxygenation as defined by the berlin ards criteria (27): timing: within 1 week of onset of symptoms imaging: bilateral pulmonary infiltrates oxygenation (any): mild: 200 mmhg \< pao2/fio2 ≤ 300 mmhg moderate: 100 mmhg \< pao2/fio2 ≤ 200 mmhg severe: pao2/fio2 ≤ 100 mmhg and 2. requiring oxygen support in the form of high flow nasal cannula (hfnc), non-invasive positive pressure ventilation, intubation and mechanical ventilation, or initiation of ecmo and 3. any one or more of the following: 1. elevated crp (\>10 gm/dl) 2. elevated ferritin (\>1000) 3. neutrophil/lymphocyte ratio \>3.3 5. patient will receive current clinical standard of care. this includes inpatient use of remdesivir, dexamethasone, convalescent plasma, or pre-hospitalization outpatient treatment with casirivimab and imdevima 6. age ≥ 18 years

inclusion criteria: subject inclusion criteria patient or legally authorized representative (lar) willing and able to provide written or electronic or otherwise fda-acceptable informed consent based on current fda regulations. hospitalized male or non-pregnant female rt-pcr confirmed sars-cov-2 using who consensus or validated primers meet the following criteria: deficiency in oxygenation as defined by the berlin ards criteria (27): timing: within 1 week of onset of symptoms imaging: bilateral pulmonary infiltrates oxygenation (any): mild: 200 mmhg < pao2/fio2 ≤ 300 mmhg moderate: 100 mmhg < pao2/fio2 ≤ 200 mmhg severe: pao2/fio2 ≤ 100 mmhg and requiring oxygen support in the form of high flow nasal cannula (hfnc), non-invasive positive pressure ventilation, intubation and mechanical ventilation, or initiation of ecmo and any one or more of the following: elevated crp (>10 gm/dl) elevated ferritin (>1000) neutrophil/lymphocyte ratio >3.3 patient will receive current clinical standard of care. this includes inpatient use of remdesivir, dexamethasone, convalescent plasma, or pre-hospitalization outpatient treatment with casirivimab and imdevima age ≥ 18 years

inclusion criteria: subject inclusion criteria patient or legally authorized representative (lar) willing and able to provide written or electronic or otherwise fda-acceptable informed consent based on current fda regulations. hospitalized male or non-pregnant female rt-pcr confirmed sars-cov-2 using who consensus or validated primers meet the following criteria: deficiency in oxygenation as defined by the berlin ards criteria (27): timing: within 1 week of onset of symptoms imaging: bilateral pulmonary infiltrates oxygenation (any): mild: 200 mmhg < pao2/fio2 ≤ 300 mmhg moderate: 100 mmhg < pao2/fio2 ≤ 200 mmhg severe: pao2/fio2 ≤ 100 mmhg and requiring oxygen support in the form of high flow nasal cannula (hfnc), non-invasive positive pressure ventilation, intubation and mechanical ventilation, or initiation of ecmo and any one or more of the following: elevated crp (>10 gm/dl) elevated ferritin (>1000) neutrophil/lymphocyte ratio >3.3 patient will receive current clinical standard of care. this includes inpatient use of remdesivir, dexamethasone, convalescent plasma, or pre-hospitalization outpatient treatment with casirivimab and imdevima age ≥ 18 years

inclusion criteria: subject inclusion criteria 1. patient or legally authorized representative (lar) willing and able to provide written or electronic or otherwise fda-acceptable informed consent based on current fda regulations. 2. hospitalized male or non-pregnant female 3. rt-pcr confirmed sars-cov-2 using who consensus or validated primers 4. meet the following criteria: 1. deficiency in oxygenation as defined by the berlin ards criteria (27): timing: within 1 week of onset of symptoms imaging: bilateral pulmonary infiltrates oxygenation (any): mild: 200 mmhg < pao2/fio2 ≤ 300 mmhg moderate: 100 mmhg < pao2/fio2 ≤ 200 mmhg severe: pao2/fio2 ≤ 100 mmhg and 2. requiring oxygen support in the form of high flow nasal cannula (hfnc), non-invasive positive pressure ventilation, intubation and mechanical ventilation, or initiation of ecmo and 3. any one or more of the following: 1. elevated crp (>10 gm/dl) 2. elevated ferritin (>1000) 3. neutrophil/lymphocyte ratio >3.3 5. patient will receive current clinical standard of care. this includes inpatient use of remdesivir, dexamethasone, convalescent plasma, or pre-hospitalization outpatient treatment with casirivimab and imdevima 6. age ≥ 18 years

inclusion criteria: subject inclusion criteria 1. patient or legally authorized representative (lar) willing and able to provide written or electronic or otherwise fda-acceptable informed consent based on current fda regulations. 2. hospitalized male or non-pregnant female 3. rt-pcr confirmed sars-cov-2 using who consensus or validated primers 4. meet the following criteria: 1. deficiency in oxygenation as defined by the berlin ards criteria (27): timing: within 1 week of onset of symptoms imaging: bilateral pulmonary infiltrates oxygenation (any): mild: 200 mmhg < pao2/fio2 ≤ 300 mmhg moderate: 100 mmhg < pao2/fio2 ≤ 200 mmhg severe: pao2/fio2 ≤ 100 mmhg and 2. requiring oxygen support in the form of high flow nasal cannula (hfnc), non-invasive positive pressure ventilation, intubation and mechanical ventilation, or initiation of ecmo and 3. any one or more of the following: 1. elevated crp (>10 gm/dl) 2. elevated ferritin (>1000) 3. neutrophil/lymphocyte ratio >3.3 5. patient will receive current clinical standard of care. this includes inpatient use of remdesivir, dexamethasone, convalescent plasma, or pre-hospitalization outpatient treatment with casirivimab and imdevima 6. age ≥ 18 years